Weight Loss & Body Composition
Tesamorelin
An FDA-approved GHRH analog studied for reducing deep abdominal (visceral) fat.
Also called: Egrifta, tesamorelin acetate
Used for
Weight Loss & Body Composition
Our pricing
$100 to $1,000+ depending on peptide and quantity
Studied for
Visceral fat in HIV-associated lipodystrophy (FDA-approved use) · Visceral fat in adults without HIV (off-label)
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH) that prompts the pituitary to release more of the body's own growth hormone. It was FDA-approved in 2010 under the brand name Egrifta to reduce excess abdominal (visceral) fat in adults with HIV-associated lipodystrophy, where trials showed roughly a 15 percent reduction in visceral fat over 26 to 52 weeks. Use for visceral fat in people without HIV is common but off-label, and the fat tends to return once the drug is stopped.
What is Tesamorelin?
Tesamorelin is a stabilized version of the full 44-amino-acid GHRH molecule, modified at one end so it resists the enzymes that normally break GHRH down within minutes. That gives it a longer action than sermorelin while still working upstream of the pituitary, which keeps the body's natural feedback controls in place and releases growth hormone in pulses rather than a constant flood.
Its claim to fame is specificity for visceral adipose tissue, the metabolically active fat packed around the abdominal organs that drives insulin resistance, fatty liver and cardiovascular risk. In the pivotal trials, tesamorelin reduced visceral fat measured by CT scan while leaving subcutaneous fat, the pinchable layer under the skin, largely unchanged. That is why it is discussed for stubborn belly fat that does not respond to diet and exercise alone.
Two things keep it honest. First, the approved population is narrow: adults with HIV whose antiretroviral therapy caused abnormal fat accumulation. Second, the effect is not permanent. When patients in the trials stopped tesamorelin, visceral fat returned toward baseline within months, so it is understood as a treatment that works while it is being taken, not a reset.
What Tesamorelin is studied for
The goals researchers and clinicians have focused on, and why patients ask about it.
Visceral fat in HIV-associated lipodystrophy (FDA-approved use)
Two large randomized, placebo-controlled trials over 26 weeks, with extensions to 52 weeks, showed an average visceral-fat reduction of about 15 percent versus placebo, along with modest improvements in triglycerides and patient-reported belly appearance. This is the only use the FDA has reviewed.
Visceral fat in adults without HIV (off-label)
Smaller studies in adults with abdominal obesity and in people with nonalcoholic fatty liver disease suggest similar visceral-fat and liver-fat reductions. These trials were shorter and enrolled fewer people, and no long-term outcome data exist in this group.
Liver fat and metabolic markers
A randomized trial in people with HIV and fatty liver found tesamorelin reduced liver fat and slowed progression of liver fibrosis over a year. Whether that extends to fatty liver in the general population is being studied and is not established.
Cognition in older adults
A small randomized trial of tesamorelin in healthy older adults and those with mild cognitive impairment reported improvements on some cognitive tests over 20 weeks, a finding some patients say lines up with sharper focus they notice while on treatment. Interest in this area is still growing, and research at a larger scale is ahead.
The human side
What patients commonly report with Tesamorelin
Clinical trials move slowly; patient experience moves faster. Here is what people using Tesamorelin under clinical supervision most often describe. Results vary from person to person.
A visibly flatter, tighter midsection despite little change on the scale
Better-fitting clothes and less bloating around the middle
Improved energy and confidence as visceral fat comes down
Motivating waist-circumference and InBody progress over a treatment course
How Tesamorelin is typically used
Tesamorelin is given as a subcutaneous injection into the abdomen. Because the effect builds over months and reverses after stopping, protocols are planned as an extended course with a defined checkpoint, usually around the same 26-week mark the trials used, at which the nurse practitioner reviews measured change and decides whether to continue.
Baseline and follow-up measurements matter more with tesamorelin than with most peptides, because its benefit is specifically visceral fat rather than scale weight. Waist circumference, InBody body-composition analysis and metabolic labs including IGF-1 and glucose are checked before starting and rechecked during treatment. Dosing and duration are individual clinical decisions and are not published here.
Tesamorelin is a companion to a supervised weight-loss and nutrition plan, not a replacement for one. It does not meaningfully reduce total body weight on its own, and the approved labeling makes no weight-loss claim.
Who tends to do well with it
Adults with HIV-associated lipodystrophy and excess abdominal fat (the FDA-approved population)
Adults with measured excess visceral fat and metabolic markers such as fatty liver or high triglycerides who have not responded to lifestyle changes and understand the use is off-label
Patients in a supervised weight-loss program who want a targeted visceral-fat strategy with objective tracking
When we take extra care
Anyone with active cancer or a recent cancer history: the label contraindicates use in active malignancy because growth hormone and IGF-1 can promote cell growth
Pregnant patients (contraindicated) and breastfeeding patients (no data)
People with a disrupted hypothalamic-pituitary axis from tumor, surgery, radiation or head trauma, in whom it will not work and is contraindicated
People with diabetes or prediabetes, since it can worsen glucose tolerance and requires closer monitoring
Anyone with fluid-retention conditions such as heart failure, or with carpal tunnel or joint problems that growth hormone can aggravate
What to know before you start
Injection-site reactions including redness, itching, pain and bruising are the most common reported effects.
Joint pain, swelling of the hands and feet (fluid retention), muscle aches and tingling or numbness are reported, consistent with raising growth hormone.
Tesamorelin can reduce glucose tolerance and raise blood sugar; the label recommends monitoring in people at risk for diabetes.
Visceral fat returns toward baseline after stopping, so benefits are not maintained without continued use.
Long-term safety of sustained IGF-1 elevation, including cancer risk, has not been established in people without HIV; hypersensitivity reactions have been reported.
Where Tesamorelin stands with the FDA
Tesamorelin is an FDA-approved drug. It was approved in 2010 as Egrifta (tesamorelin acetate) to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, and a higher-concentration formulation was approved later. Use for visceral fat in people without HIV, or for any metabolic, liver or cognitive goal, is off-label and has not been reviewed by the FDA. Because an approved drug exists, compounded versions occupy a different regulatory position than the brand product; whether a compounded or brand version is appropriate for you, and what is available, is decided at your consultation under the rules in force at that time.
Source: FDA compounding guidanceWhat Tesamorelin typically costs
At Hormones + Weight Loss, peptide pricing runs from about $100 to $1,000 or more depending on the peptide and the quantity you order, and many patients start with a single peptide on a short cycle. Your exact cost is quoted after your consultation.
Brand Egrifta versus a compounded version
Whether insurance covers it, which is generally limited to the HIV-lipodystrophy indication
Whether InBody tracking, IGF-1 and metabolic labs are bundled with the consultation
Often combined with
Peptides are an add-on, not a plan. At Hormones + Weight Loss they are considered inside a broader, lab-guided program.
Tesamorelin FAQs
Tesamorelin prompts the pituitary to release more of your own growth hormone, which preferentially reduces visceral fat, the deep fat around the abdominal organs. In FDA trials it cut visceral fat by about 15 percent over 26 to 52 weeks while leaving subcutaneous fat mostly unchanged. The effect reverses after stopping.
Yes. It was approved in 2010 as Egrifta for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Using it for visceral fat in people without HIV, or for fatty liver or cognition, is off-label: legal for a licensed prescriber to consider, but not FDA-reviewed for those goals.
Not much on the scale. Tesamorelin targets visceral fat specifically, and trial participants lost little total body weight. Waist circumference and body-composition measurements change more than the scale does, which is why it is paired with a supervised weight-loss plan rather than used alone.
The most common are injection-site reactions, joint pain, swelling in the hands and feet, muscle aches and tingling. It can raise blood sugar, so glucose is monitored. It is contraindicated in active cancer, pregnancy and pituitary or hypothalamic disruption, and the long-term effects of raised IGF-1 in people without HIV are not established.
Peptide therapy at Hormones + Weight Loss ranges from about $100 to $1,000 or more, depending on the peptide and the quantity ordered. Where Tesamorelin lands inside that range depends on the form, the cycle length and whether it is combined with other care. Your exact cost is quoted after your consultation and labs.
Hormones + Weight Loss discusses peptide options, including tesamorelin, at our Meridian, Twin Falls and Lewiston clinics, with Boise-area patients seen in Meridian. A consultation with a nurse practitioner, usually with InBody and metabolic labs, determines whether it fits your goals and can be prescribed under current rules.
Both are GHRH analogs that stimulate your own growth hormone. Tesamorelin is a stabilized full-length molecule with a current FDA approval and randomized trials showing visceral-fat reduction. Sermorelin is a shorter fragment with a discontinued pediatric approval and weaker adult evidence, but it typically costs less.
Related peptides
Growth-Hormone Support
Sermorelin
A GHRH analog studied for prompting your own pituitary to release growth hormone.
Growth-Hormone Support
CJC-1295 / Ipamorelin
A GHRH analog plus a ghrelin-receptor agonist studied together for growth-hormone release.
Weight Loss & Body Composition
Retatrutide
An investigational triple-agonist weight-loss drug in Phase 3 trials; not yet approved or available.
Weight Loss & Body Composition
AOD-9604
A growth-hormone fragment studied for fat metabolism, with renewed interest from newer research.
Peptide therapy near you in Idaho
Consultations at all three clinics. Boise-area patients are seen at our Meridian clinic, minutes off Eagle Road and I-84.
Meridian
2572 N Stokesberry Pl #300
Meridian, ID 83646
Mon–Fri 8am–6pm
Twin Falls
496 Shoup Ave West Ste E
Twin Falls, ID 83301
Mon–Thu 8am–6pm
Lewiston
1630 23rd Ave Ste 1201A
Lewiston, ID 83501
Mon–Wed 8am–6pm
Educational content only. It does not replace an evaluation by a licensed clinician. Whether a peptide fits you is decided at your consultation.
Wondering whether Tesamorelin fits your goals?
Start with a consultation and labs. A nurse practitioner will walk through the evidence, the current rules, and whether any peptide belongs in your plan.